Premium
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I‐II non‐hodgkin's lymphomas
Author(s) -
Nissen Nis I.,
Ersbøll Jens,
Hansen Hanne Sand,
WalbomJørgensen Sven,
PedersenBjergaard Jens,
Hansen Mogens Mørk,
Rygård Jørgen
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830701)52:1<1::aid-cncr2820520102>3.0.co;2-m
Subject(s) - medicine , vincristine , radiation therapy , histology , cyclophosphamide , stage (stratigraphy) , prednisone , chemotherapy , working formulation , lymphoma , randomized controlled trial , adjuvant , oncology , surgery , non hodgkin's lymphoma , paleontology , biology
In a randomized, prospective trial from 1974–1978, 73 patients with non‐Hodgkin's lymphomas in clinical Stage I or II were treated with extended field radiotherapy alone (RT) or RT plus adjuvant chemotherapy with vincristine, streptonigrin, cyclophosphamide and prednisone (RT + CT). With a median follow‐up time of five years, 54% have relapsed in the RT group versus only 10% in the RT + CT group ( P < 0.01). There is no statistical difference in the overall survival yet, but 13/14 deaths in the RT group versus only 3/12 in the RT + CT group were due to progressive disease. Among patients with unfavorable histology, 13/22 in the RT group have died from disease progression against 3/34 in the RT + CT group ( P < 0.01). The results are in agreement with those from two other series published in detail. Based on these results we therefore recommend to use adjuvant CT with RT in all Stage I‐II patients with unfavorable histology. Further observation is necessary before a conclusion can be drawn for the lymphoma patients with more favorable histology. Cancer 52:1–7, 1983.